secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001641172-25-014858
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Hepion shareholders reject reverse stock split amendment at 2025 annual meeting
-------------------------------------------------------------------------------

- Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
- All four director nominees (Brancaccio, Block, Lbiati, Purcell) elected despite majority of votes withheld.
- Ratification of Grassi & Co. as auditors passed with 4.76M for vs 1.17M against.
- Advisory say-on-pay failed with 162K for, 337K against.
- Only 10.9M shares outstanding; broker non-votes totaled 5.46M on most proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225014858/0001641172-25-014858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225014858/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer